Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to October 2007

October 2007

Men’s Waist Size Linked with Urinary Symptoms

The bigger the waistline, the poorer an older man’s voiding and sexual function, new research indicates.* Larger waist circumference is a characteristic of metabolic syndrome, which is linked with a higher risk of heart disease and diabetes.

Dr. Steven A. Kaplan of Weill Cornell Medical College in New York studied whether waist size is a useful predictor of prostate volume and the severity of pelvic dysfunction in older men. Examining 88 men of average age 62 years with moderate-to-severe untreated urinary symptoms who were grouped according to their waist circumference, Dr. Kaplan and his colleagues found that prostate volume, prostate specific antigen level (a marker for prostate enlargement or disease), voiding symptoms, erectile dysfunction, and ejaculatory dysfunction all increased as the waistline did.

The scientists concluded that obese men are at increased risk of pelvic dysfunction and can be “easily diagnosed” by measuring waist circumference.

—Cathy Burke


* Available at: conditions/06/14/men.obese.urinary.reut/. Accessed July 9, 2007.

Magnesium May Protect Against Diabetes

Eating more magnesium-rich foods, like green leafy vegetables and nuts, may reduce the risk of diabetes, according to a recent meta-analysis.*

Seven studies involving more than 280,000 participants revealed that for every 100 mg increase in magnesium intake, the risk of developing type 2 diabetes decreased by 15%, according to the reviewers in Sweden who called the results “compelling.”

Dietary sources of magnesium include green leafy vegetables, grains, nuts, and milk. The RDA for magnesium is 320 mg per day for women and 420 mg per day for men, yet many adults fail to achieve these modest amounts of the mineral. The protective role of magnesium intake against diabetes may be due to improvement in insulin sensitivity.

Given the devastating consequences of diabetes, increased consumption of magnesium-rich foods and supplements seems prudent.

—Cathy Burke


* Available at: Accessed July 10, 2007.

Estrogen Therapy Associated with Less Coronary Plaque

Women worried about the link between estrogen and cardiovascular disease can take heart in new information from a Women’s Health Initiative study suggesting a potential cardioprotective role for the hormone.*

The ancillary study of 1,064 women between 50 and 59 years compared those taking estrogen with those taking a placebo. After treatment ended, researchers measured the level of calcium-containing plaque, a marker for future cardiovascular disease, in the women’s coronary arteries. Their conclusion: Those who’d taken estrogen had less coronary artery calcium compared with those taking placebo.

“Although our findings lend support to the theory that estrogen may slow early stages of plaque build-up in the coronary arteries, estrogen has complex effects and other noted health risks,” noted the study’s lead author, Dr. JoAnn Manson.

—Cathy Burke


* Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007 Jun 21;356(25):2591-602.

Novel Cancer Drug Shows Promise

Geron Corporation announced recently that its experimental anti-cancer drug, currently dubbed GRN163L, has exhibited good tolerability in Phase I/II trials in patients suffering from chronic lymphocytic leukemia (CLL).* Although far from reaching the market, the drug has demonstrated good tolerability and the ability to reach desirable concentrations in patients’ bloodstreams in a predictable, linear manner. These properties simplify dosing and reduce the chance of overdose, should the drug gain eventual FDA approval.

The drug is the world’s first to target telomerase that has reached the clinical trial stage. Telomerase is an enzyme enlisted by many tumors and cancer cells to fuel runaway growth. According to Geron, it appears to be “unique in its observed effects on tumor stem cells.” Such cells are rare, chemotherapy-resistant cells responsible for cancer recurrence. Future trials will focus on treating multiple myeloma and non-small cell lung carcinoma.

—Dale Kiefer


* Available at: Accessed July 10, 2007.

Low Vitamin D Levels May Increase Cardiovascular Risk

Low blood levels of vitamin D are linked with increased cardiovascular risk factors in American adults, according to a recent study.*

Scientists measured serum levels of 25-hydroxyvitamin D in more than 15,000 men and women aged 20 years and older. Those with the lowest vitamin D levels had a significantly higher prevalence of hypertension, diabetes, and elevated serum triglyceride levels—all of which increase cardiovascular disease risk.

Low vitamin D levels were found in women, the elderly, and obese individuals.

These study findings suggest that low serum vitamin D could represent a novel cardiovascular risk factor, and that current recommendations for vitamin D intake may be far too low for optimal health. Prospective studies are needed to assess vitamin D’s effects on various cardiovascular risk factors.

—Cathy Burke


* Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007 Jun 11;167(11):1159-65.

Cinnamon Prevents Blood Sugar Spikes

Cinnamon helps diminish the blood glucose spike that typically follows a meal, in part by delaying stomach emptying, according to new research from Sweden.1 Scientists have previously reported that cinnamon lowers fasting blood sugar, low-density lipoprotein (LDL), and total cholesterol in patients with type 2 diabetes.

The Swedish study examined the effects of 6 g of cinnamon added to approximately 10 ounces of rice pudding consumed by 14 non-diabetic subjects. “The addition of cinnamon to the rice pudding significantly delayed gastric emptying and lowered the [after-meal] glucose response,” wrote the researchers.

Cinnamon’s water-soluble polyphenols may be responsible for its beneficial metabolic effects.2

—Dale Kiefer


1. Hlebowicz J, Darwiche G, Bjorgell O, Almer LO. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr. 2007 Jun;85(6):1552-6.
2. Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004 Jan 14;52(1):65-70.

Omega-3 Fatty Acids May Protect Against Prostate Cancer

A diet higher in omega-3 fatty acids may improve the prognosis in those who are genetically prone to developing prostate cancer, according to a recent report.1

To study the effect of fatty acids on prostate cancer, scientists utilized mice with a genetically determined susceptibility to the disease. Omega-3 fatty acids reduced prostate tumor growth, slowed progression, and increased survival, while omega-6 fatty acids had opposite effects.

“Diet can tip the balance toward a good or a bad outcome,” noted one of the scientists. “Our data imply a beneficial effect of omega-3 [fatty acids] on delaying the onset of human prostate cancer.”

Omega-3s, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in cold water fish and fish oil supplements. The present study adds to a growing body of evidence that omega-3s are protective against cancer.2

—Dale Kiefer


1. Berquin IM, Min Y, Wu R, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007 Jul 2;117(7):1866-75.
2. Theodoratou E, McNeill G, Cetnarskyj R, et al. Dietary fatty acids and colorectal cancer: a case-control study. Am J Epidemiol. 2007 Jul 15;166(2):181-95.

Flavonoid Consumption Slows Cognitive Decline

Abundant intake of dietary flavonoids helps protect against cognitive decline, according to a newly published study from France.* Present in a wide variety of fruits and vegetables, flavonoids are naturally occurring antioxidants.

Scientists enrolled more than 1,600 men and women aged 65 years or older who were initially dementia-free, and assessed their dietary intake of flavonoids. Subjects’ cognitive performance levels were assessed at baseline and several times thereafter for one decade.

Higher flavonoid intake at baseline was associated with better cognitive performance, after adjustment for other factors. By the end of the 10-year study period, subjects with the lowest flavonoid intake experienced nearly twice the rate of cognitive decline as subjects in the highest-intake groups.

“This study raises the possibility that dietary flavonoid intake is associated with better cognitive evolution,” concluded the scientists.

—Dale Kiefer


* Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, Barberger-Gateau P. Flavonoid intake and cognitive decline over a 10-year period. Am J Epidemiol. 2007 Jun15;165(2):1364-71.